Hiltonol
Other / unclassified targets BCAR3, TLR3 via activation
Trials 67 · started per year
Also used as a comparator or background therapy in 62 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT07605520 Background | May 2026 → May 2028 expected | — | ANRS, Emerging Infectious Diseases | Recruiting | No outcome recorded |
| Phase 0 | NCT07077616 Background | Jul 2025 → Dec 2027 expected | glioma | Biogenea Pharmaceuticals Ltd. | Recruiting | No outcome recorded |
| Phase 0 | NCT00874861 Background | Apr 2009 → May 2012 | astrocytoma (excluding glioblastoma), oligoastrocytoma, oligodendroglioma | Ian F. Pollack, M.D. | Completed | No outcome recorded |
| Phase 139 trials | ||||||
| Phase 1 | NCT07300475 Background | Aug 2026 → May 2030 expected | triple-negative breast carcinoma | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07430202 Background | Aug 2026 → Aug 2030 expected | fibrolamellar hepatocellular carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06665646 Background | Sep 2025 → Jul 2026 overdue | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 1 | NCT06411691 Background | Jun 2025 → Mar 2028 expected | colorectal cancer, malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1 | NCT06529822 Background | Mar 2025 → Jan 2030 expected | gastroesophageal adenocarcinoma, infiltrating bladder urothelial carcinoma, melanoma, non-small cell lung carcinoma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT05457959 Background | Dec 2024 → Dec 2029 | diffuse glioma, H3 G34 mutant | Jonsson Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT06342908 Background | Jun 2024 → Mar 2027 expected | diffuse glioma, H3 G34 mutant | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05283109 Background | Aug 2023 → Apr 2025 overdue | malignant glioma | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04799431 Background | May 2023 | colorectal cancer, pancreatic ductal adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Withdrawn | No outcome recorded |
| Phase 1 | NCT05025488 Background | Apr 2023 → Mar 2027 expected | essential thrombocythemia, myelofibrosis | Marina Kremyanskaya | Recruiting | No outcome recorded |
| Phase 1 | NCT04616248 Background | Jan 2023 → Jan 2027 expected | basal cell carcinoma, bone sarcoma, breast carcinoma, cutaneous neuroendocrine carcinoma +3 | University of Southern California | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05111353 Background | Dec 2022 → Nov 2025 | malignant pancreatic neoplasm | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT05254184 Background | Nov 2022 → Apr 2027 expected | non-small cell lung carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1 | NCT05098210 Background | Jun 2022 → Nov 2027 expected | acral lentiginous melanoma, female breast carcinoma, hormone receptor-positive breast cancer, malignant conjunctival melanoma +3 | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05013216 Background | Apr 2022 → Oct 2027 expected | hereditary neoplastic syndrome, malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1 | NCT05010200 Background | Jan 2022 → Jan 2027 expected | prostate cancer | Ashutosh Kumar Tewari | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03068832 Background | Sep 2021 → Mar 2023 | brain cancer | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT04749641 Background | Mar 2021 → Oct 2024 | diffuse intrinsic pontine glioma | Yang Zhang | Completed | No outcome recorded |
| Phase 1 | NCT04117087 Background | May 2020 → Jun 2027 expected | colorectal cancer, malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04248569 Background | Apr 2020 → Mar 2029 expected | fibrolamellar hepatocellular carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1 | NCT03956056 Background | Feb 2020 → Jul 2022 | malignant pancreatic neoplasm | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT04201873 Background | Jan 2020 → Aug 2026 overdue | glioblastoma | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03359239 Background | May 2019 → Oct 2021 | urothelial carcinoma | Matthew Galsky | Completed | No outcome recorded |
| Phase 1 | NCT03166254 Background | Apr 2019 → Jun 2022 | non-small cell lung carcinoma, small cell lung carcinoma | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT03422094 Background | Oct 2018 → Apr 2020 | glioblastoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT03121677 Background | Oct 2018 → Sep 2020 | follicular lymphoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT03558945 Background | Jul 2018 → Nov 2023 | pancreatic neoplasm | Anda Biopharmaceutical Development (Shenzhen) Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02947854 Background | Sep 2016 → Mar 2018 | — | PCI Biotech AS | Completed | No outcome recorded |
| Phase 1 | NCT02826434 Background | Aug 2016 → Dec 2026 expected | breast cancer | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02721043 Background | Apr 2016 → Nov 2019 | cancer | Nina Bhardwaj | Completed | No outcome recorded |
| Phase 1 | NCT02427581 Background | Sep 2015 → Dec 2025 | triple-negative breast carcinoma | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT02287428 Background | Nov 2014 → Feb 2027 expected | glioblastoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02149225 Background | Oct 2014 → Jun 2018 | glioblastoma | Immatics Biotechnologies GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01810016 Background | Jan 2014 → May 2016 | metastatic melanoma | Ludwig Institute for Cancer Research | Terminated | No outcome recorded |
| Phase 1 | NCT01834248 Background | Jul 2013 → Jun 2015 | acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent, chronic myelomonocytic leukemia, refractory anemia with excess blasts in transformation | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT01241162 Background | Aug 2010 → Oct 2016 | Ewing sarcoma, neuroblastoma, osteosarcoma, rhabdomyosarcoma +1 | University of Louisville | Completed | No outcome recorded |
| Phase 1 | NCT01012700 Comparator | Nov 2009 → Apr 2010 | — | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT01008527 Background | Oct 2009 → Sep 2013 | melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT01130077 Background | Feb 2009 → Nov 2024 | childhood brain stem glioma, childhood low-grade glioma, pediatric high-grade glioma | James Felker | Completed | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT06782932 Background | May 2025 → Dec 2028 expected | pancreatic adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06614140 Background | Nov 2022 → Aug 2025 | cancer | Seqker Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04364230 Background | Sep 2020 → Mar 2024 | uveal melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 1/2 | NCT03665545 Background | Oct 2018 → Dec 2023 | adult glioblastoma, brain glioblastoma | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 1/2 | NCT02661100 Background | Jan 2017 → Jul 2018 | melanoma, mesothelioma, non-small cell lung carcinoma, small cell lung carcinoma +2 | Case Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02960230 Background | Nov 2016 → Dec 2023 | diffuse midline glioma, H3 K27M-mutant | Sabine Mueller, MD, PhD | Completed | No outcome recorded |
| Phase 1/2 | NCT02332889 Background | Apr 2015 → Jul 2016 | glioma, medulloblastoma, primitive neuroectodermal tumor | University of Louisville | Terminated | No outcome recorded |
| Phase 1/2 | NCT02078648 Background | May 2014 → Sep 2017 | adult glioblastoma | Stemline Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01720836 Background | Nov 2012 → Oct 2027 expected | non-small cell lung carcinoma | Olivera Finn | Recruiting | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT06343077 Comparator | Jan 2024 → Dec 2026 expected | — | Ashutosh Kumar Tewari | Recruiting | No outcome recorded |
| Phase 2 | NCT03606967 Background | Apr 2021 → Dec 2026 expected | invasive breast carcinoma, triple-negative breast carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT02873819 Background | Mar 2017 → May 2021 | oral cavity squamous cell carcinoma | Gliknik Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02754362 Background | Nov 2016 → Jun 2019 | glioblastoma | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 2 | NCT02334735 Background | Jul 2015 → Jul 2020 | melanoma | Nina Bhardwaj | Completed | No outcome recorded |
| Phase 2 | NCT02129075 Background | Apr 2014 → Mar 2016 | cutaneous melanoma, mucosal melanoma, ocular melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01437605 Comparator | Oct 2011 → Jul 2018 | melanoma | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT01245673 Background | May 2011 → Dec 2015 | plasma cell myeloma | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT00773097 Background | Oct 2008 → Oct 2011 | — | Robert Schoen | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05557240 Background | Sep 2022 → Feb 2024 | malignant glioma | Shanghai 10th People's Hospital | Unknown | No outcome recorded |
| — | NCT00694551 Background | Dec 2008 → Feb 2013 | prostate cancer | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 139 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hiltonol | “The purpose of this study is to test an approach of stimulating the body's immune system to attack prostate cancer. This study will test injection of a substance polylysine and...” NCT03262103 ↗32“In a recently concluded phase 1 study of CDX-1401 in combination with adjuvant Toll-like receptor agonists with Resiquimod (TLR7/8 agonist) and Hiltonol (poly-ICLC; TLR3...” NCT02661100 ↗ “Study of the Immunogenicity of the MUC1 Peptide - Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) OR HILTONOL™ Adjuvant...” NCT01720836 ↗ “inject a body defense activator, polyinosinic-polycytidylic acid polylysine carboxymethylcellulose (poly ICLC, hiltonol, oncovir), into and around the cancer to activate...” NCT00553683 ↗ “CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24” NCT04842682 ↗ “Poly-ICLC adjuvant (Hiltonol) used at a dose of 1.0 mg and will be mixed with CD40.RBDv vaccine just prior to subcutaneous injection at day 0.” NCT07605520 ↗ “Poly-ICLC (Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose, also known as Hiltonol®)” NCT03721679 ↗ “The potential protection of poly-ICLC (Hiltonol®) a double stranded RNA (dsRNA) against EBOV infection was assessed” PMID 30611774 ↗ Jan 2019 “The study is investigating a medication called Poly-ICLC (Hiltonol®, Oncovir), which is an adjuvant.” NCT02071095 ↗ “In the proposed clinical trial we will use poly ICLC (Hiltonol) from Oncovir, Inc as the adjuvant.” NCT01127464 ↗ “Poly-ICLC (also called Hiltonol) is an experimental "viral mimic" and an activator of immunity.” NCT02950766 ↗ “Poly-ICLC (also called Hiltonol) is an experimental "viral mimic" and an activator of immunity.” NCT04024878 ↗ “Poly-ICLC, (Hiltonol®, Oncovir) is a synthetic double-stranded ribo-nucleic acid (dsRNA)” NCT03665545 ↗ “Direct Injection of Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma” NCT04525859 ↗ “Dr. Salazar is an employee of Oncovir, Inc., which makes poly ICLC (Hiltonol).” PMID 37790490 ↗ Sep 2023 “Hiltonol applied topically to vaccine site before and after vaccination” NCT01241162 ↗ “mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)]” NCT06564623 ↗ “mutant KRAS peptide vaccine with Hiltonol® (Poly-ICLC)” NCT06782932 ↗ “Hiltonol is a poly-ICLC developed by the Oncovir, Inc.” NCT05281926 ↗ “Hiltonol (poly-ICLC, TLR3)” PMID 24739759 ↗ Apr 2014 “Hiltonol® (Poly-ICLC)” NCT01245673 ↗ “poly ICLC (Hiltonol)” NCT01299662 ↗ |
| Known as | Anti-MUC1 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02544880 ↗ |
| Known as | Hiltinol | “an experimental drug called polyICLC (polyinosinic-polycytidylic acid that is stabilized with carboxymethylcellulose and polylysine), also known as Hiltinol, that activates the...” NCT06472661 ↗ |
| Known as | Hiltonol (Poly-ICLC) | “Hiltonol® (Poly-ICLC)” NCT04117087 ↗5“Hiltonol® (Poly-ICLC)” NCT05013216 ↗ “Hiltonol® (Poly-ICLC)” NCT06411691 ↗ “Hiltonol® (Poly-ICLC)” NCT04248569 ↗ “Hiltonol® (Poly-ICLC)” NCT07430202 ↗ “Hiltonol® (Poly-ICLC)” NCT04799431 ↗ |
| Known as | HiltonolTM | “also known as HiltonolTM” NCT00374049 ↗ |
| Known as | ICLC | “The adjuvant poly-interstitial Cajal-like cell (ICLC; Hiltonol) will be injected immediately after and adjacent to DC vaccine site” NCT02332889 ↗ |
| Known as | oncovir | “inject a body defense activator, polyinosinic-polycytidylic acid polylysine carboxymethylcellulose (poly ICLC, hiltonol, oncovir), into and around the cancer to activate...” NCT00553683 ↗ |
| Known as | Oncovir poly IC:LC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01008527 ↗ |
| Known as | pBCAR3-phosphopeptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01846143 ↗ |
| Known as | pBCAR3126-134 | “HLA-A*0201-restricted phosphorylated BCAR3 peptide (pBCAR3126-134)” PMID 32385144 ↗ May 2020 |
| Known as | Poly ICLC: carboxymethylcellulose, polyinosinic-polycytidylic acid & poly-L-lysine double-stranded RNA | “Poly ICLC: carboxymethylcellulose, polyinosinic-polycytidylic acid & poly-L-lysine double-stranded RNA” NCT01079741 ↗ |
| Known as | poly-ICLC | “The purpose of this study is to test an approach of stimulating the body's immune system to attack prostate cancer. This study will test injection of a substance polylysine and...” NCT03262103 ↗125“Using antigens eluted from the surface of glioblastoma samples, we designed a phase I/II study to test safety and immunogenicity of the IMA950 multipeptide vaccine adjuvanted...” PMID 30753611 ↗ Jul 2019 “This phase II study was designed to determine the objective response rate and 6-month progression free survival of adult patients with recurrent supratentorial anaplastic...” PMID 18850068 ↗ Oct 2008 “Study of the Immunogenicity of the MUC1 Peptide - Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) OR HILTONOL™ Adjuvant...” NCT01720836 ↗ “The researched vaccine, containing H3.3-K27M-targeting neoantigen peptides and poly ICLC, will be administered through subcutaneous injection into DIPG patients after they...” NCT04749641 ↗ “To determine the most effective combination of autologous tumor lysate-pulsed DC vaccination, with or without the adjuvant toll-like receptor (TLR) agonists poly-ICLC or...” PMID 37790490 ↗ Sep 2023 “NY-ESO-1 recombinant protein (250 µg) was mixed with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3...” NCT01810016 ↗ “TAMAVAQ Vaccine plus Poly-ICLC, cGAMP, Granulocyte-macrophage colony stimulating factor (GM-CSF), imiquimod, CpG oligodeoxynucleotides, saponins and monophosphoryl lipid A (MPLA)” NCT07077616 ↗ “This is a phase II, prospective, longitudinal, multi-center trial of poly-ICLC (Hiltonol ®) treatment for progressive low-grade gliomas in pediatric patients with NF1.” NCT04544007 ↗ “The primary objective is to evaluate the immunogenicity of a combination of the 100mer MUC1 peptide and adjuvant Poly-ICLC in boosting the immune response to MUC1.” NCT00773097 ↗ “CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24” NCT04842682 ↗ “Poly-ICLC adjuvant (Hiltonol) used at a dose of 1.0 mg and will be mixed with CD40.RBDv vaccine just prior to subcutaneous injection at day 0.” NCT07605520 ↗ “A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients” NCT05281926 ↗ “Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine.” NCT02960230 ↗ “The vaccine will consist of up to 20 peptides as well as a drug that activates the immune system called Poly-ICLC.” NCT04024878 ↗ “Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension.” NCT03068832 ↗ “Poly-ICLC (also called Hiltonol) is an experimental "viral mimic" and an activator of immunity.” NCT02950766 ↗ “Poly-ICLC at 10µg/kg and up to 1640 µg/injection will be administered intramuscularly (i.m.)” NCT00766753 ↗ “CDX-1307 vaccine co-administered with immune adjuvants (GM-CSF, Poly-ICLC and Resiquimod)” NCT01094496 ↗ “conjunction with toll-like receptor (TLR)-3 agonist poly-ICLC, is a promising approach” PMID 28388966 ↗ Apr 2017 “Direct Injection of Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma” NCT04525859 ↗ “Direct Injection of Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma” NCT04525859 ↗ “A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas” NCT01188096 ↗ “-NEO-PV-01 is combined with the adjuvant poly-ICLC prior to administration.” NCT03166254 ↗ “Poly-ICLC (Hiltonol®) treatment alone or in combination with anti-PD-1” NCT02423863 ↗ “Pretreatment with Poly-ICLC alone week 1 \&2 (50 ug/kg 3 days/week)” NCT00374049 ↗ “Hiltonol®, (Poly IC:LC), a potent immunomodulator, is a synthetic,” PMID 27956136 ↗ Dec 2016 “2. Drug: 0.3 mg DNAJB1-PRKACA peptide vaccine + 0.5 mg Poly-ICLC” NCT07430202 ↗ “Drug: 0.3 mg DNAJB1-PRKACA peptide vaccine + 0.5mg Poly-ICLC” NCT04248569 ↗ “Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC” NCT05013216 ↗ “mutant KRAS peptide vaccine with Hiltonol® (Poly-ICLC)” NCT06782932 ↗ “polyinosinic-polycytidylic acid (poly-ICLC) adjuvant” NCT05254184 ↗ “up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC” NCT04117087 ↗ “0.5 mg of poly-ICLC as the adjuvant for each pool” NCT03558945 ↗ “poly-ICLC (TLR3 agonist that activates DCs)” PMID 35121932 ↗ Nov 2020 “MUC1 peptide-poly-ICLC adjuvant vaccine” NCT00986609 ↗ “Biological: Vaccine + PolyICLC” NCT01720836 ↗ “Poly-ICLC is a TLR3 agonist.” NCT04116320 ↗ “ten (10) doses of Poly-ICLC.” NCT05025488 ↗ “Hiltonol (Poly-ICLC)” NCT02947854 ↗ “Hiltonol (poly ICLC)” NCT01012700 ↗ “1.5 mg of poly-ICLC” NCT03422094 ↗ “Drug: Poly ICLC” NCT01188096 ↗ |
| Known as | Poly-ICLC (Hiltonol, Oncovir) | “Poly-ICLC (Hiltonol®, Oncovir)” NCT02071095 ↗ |
| Known as | Polyinosinic-Polycytidylic acid | “Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose (Poly-ICLC)” NCT00646152 ↗1“polyinosinic-polycytidylic acid (poly-ICLC) adjuvant” NCT05254184 ↗ |
| Known as | polyinosinic-polycytidylic acid - poly-L-lysine carboxymethylcellulose | “polyinosinic-polycytidylic acid - poly-L-lysine carboxymethylcellulose (poly-ICLC)” NCT00616941 ↗ |
| Known as | polyinosinic-polycytidylic acid polylysine carboxymethylcellulose | “inject a body defense activator, polyinosinic-polycytidylic acid polylysine carboxymethylcellulose (poly ICLC, hiltonol, oncovir), into and around the cancer to activate...” NCT00553683 ↗ |
| Known as | polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose | “This phase II study was designed to determine the objective response rate and 6-month progression free survival of adult patients with recurrent supratentorial anaplastic...” PMID 18850068 ↗ Oct 20086“PURPOSE: This phase II study was designed to determine the overall survival time of adults with supratentorial glioblastoma treated with the immune modulator,...” PMID 18797818 ↗ Sep 2008 “Study of the Immunogenicity of the MUC1 Peptide - Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) OR HILTONOL™ Adjuvant...” NCT01720836 ↗ “Polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC) (10-50 mcg/kg, administered intramuscularly one to three times weekly) was...” PMID 8727138 ↗ Jun 1996 “Poly-ICLC (Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose, also known as Hiltonol®)” NCT03721679 ↗ “Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) or HiltonolTM” NCT00374049 ↗ “SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)” NCT02078648 ↗ |
| Known as | polyinosinic-polycytidylic acid-poly-I-lysine carboxymethylcellulose | “polyinosinic-polycytidylic acid-poly-I-lysine carboxymethylcellulose (poly-ICLC)” PMID 32817593 ↗ Dec 2020 |
| Action | Activate | “to activate sentinel dendritic cells” NCT00553683 ↗ |
| Modality | Other / unclassified | “the immunoadjuvants Montanide and polyinosinic-polycytidylic acid - poly-L-lysine carboxymethylcellulose (poly-ICLC)” NCT00616941 ↗ |
| Route | Intramuscular | “patients receive poly ICLC intramuscularly 3 times weekly” NCT00052715 ↗ |
| Target | TLR3 | “TLR3 agonist Poly-ICLC” NCT01079741 ↗ |